<DOC>
	<DOCNO>NCT01106014</DOCNO>
	<brief_summary>The AC-065A302 GRIPHON study event-driven Phase 3 study demonstrate effect ACT-293987 time first morbidity mortality event patient pulmonary arterial hypertension .</brief_summary>
	<brief_title>Selexipag ( ACT-293987 ) Pulmonary Arterial Hypertension</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Familial Primary Pulmonary Hypertension</mesh_term>
	<mesh_term>Selexipag</mesh_term>
	<criteria>Male female patient 1875 year old , symptomatic PAH PAH belong follow subgroup update Dana Point Clinical Classification Group 1 ( Idiopathic , Heritable , Drug toxin induce , Associated ( APAH ) Connective tissue disease , Congenital heart disease simple systemictopulmonary shunt least 1 year surgical repair , HIV infection ) Documented hemodynamic diagnosis PAH right heart catheterization , perform time prior Screening Six minute walk distance ( 6MWD ) 50 450 Screening within 2 week prior Baseline Visit Signed informed consent Patients pulmonary hypertension ( PH ) Updated Dana Point Classification Groups 25 , PAH Group 1 subgroup cover inclusion criterion Patients receive prostacyclin analog within 1 month Baseline Visit , schedule receive compound trial Patients moderate severe obstructive lung disease Patients moderate severe restrictive lung disease Patients moderate severe hepatic impairment ( ChildPugh B C ) Patients document leave ventricular dysfunction Patients severe renal insufficiency Patients BMI &lt; 18.5 Kg/m2 Patients receive receive investigational drug within 1 month Baseline Visit Acute chronic impairment ( dyspnea ) , limit ability comply study requirement , particular 6MWT Recently conduct plan cardiopulmonary rehabilitation program base exercise training Psychotic , addictive disorder limit ability provide inform consent comply study requirement Life expectancy le 12 month Females lactate pregnant plan become pregnant study Known hypersensitivity excipients drug formulation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>pulmonary arterial hypertension</keyword>
	<keyword>PAH</keyword>
</DOC>